drugset / Trial / NCT07648459
CM336-SOC for Dynamically High-Risk Multiple Myeloma Study
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of CM336 combined with SOC therapy in patients with dynamically high-risk multiple myeloma.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-07-09
- Completion
- 2028-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | — | Subcutaneous |